Friday, July 31, 2026

April 2026: Korean Investors Buy 15.1 Billion USD in U.S. Stocks Despite High Exchange Rates

Despite high USD-KRW rates, Korean investors set a record with $15.113 billion in U.S. stock purchases, indicating strong demand.

North Korea’s Youth Mobilize: A Surge of Patriotism Amidst Tensions

North Korea reports 1.4M youths volunteering for military service amid rising anti-South sentiment following alleged drone incidents.

Bridging Clinic and Lab: Three Physician-Scientists Drive Next-Generation Liver Disease Research

Physician-scientists in Korea bridge clinical practice and research, driving innovations in patient care and biotechnology competitiveness.

Tag: CAR-T therapy

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Korea’s First CAR-T Therapy Clears Initial Reimbursement Hurdle, With First Prescriptions Expected in October

South Korea's first CAR-T therapy, Rimkato, moves closer to national health insurance reimbursement, with commercialization expected by year-end.

Korea’s First Domestic CAR-T Therapy Just Won Approval—and That’s a Bigger Deal Than It Sounds

CureCell's CAR-T therapy Rimkato is the first approved in South Korea, enhancing access to treatment for blood cancer patients.

Curocell’s RIMQARTO®: The First CAR-T Therapy in Korea, with Plans for Global Release

Curocell aims to lead in CAR-T therapies with RIMQARTO's approval, focusing on solid tumors and global expansion strategies.

Verismo unveils preclinical data on improved antitumor efficacy and safety of blood cancer CAR-T at AACR

HLB Innovation's SynKIR-310 shows improved antitumor activity and safety in preclinical trials, achieving 100% survival in mice.

Revolutionary CAR-T Treatment SynKIR-310 Outperforms CD19 CAR-T: What This Means for Blood Cancer Patients

Verismo Therapeutics' SynKIR-310 shows superior anti-tumor effects in preclinical studies, promising a safer CAR-T therapy for blood cancers.

HLB Group Unveils Groundbreaking Cancer Treatments at AACR 2026: What You Need to Know

HLB Group will present key findings on anti-cancer therapies at AACR 2026, highlighting SynKIR-110 and Lirafugratinib's advancements.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.